SCHEMBL20394372

SCHEMBL20394372

COc1ccc(OC)c(Br)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
NQO2 P16083 6/20 0.40
CYP1A2 P05177 1/20 0.40
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 2/20 0.36
HPGD P15428 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
SIRT1 Q96EB6 1/20 0.36
NNMT P40261 1/20 0.36
ERN1 O75460 1/20 0.36
NQO1 P15559 1/20 0.35
S1PR4 O95977 1/20 0.35
PDGFRB P09619 1/20 0.35
PDGFRA P16234 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31414709 1.00 POLB (0.41) POLBTDP1NQO2CYP1A2KMT2A
SCHEMBL2144116 0.84 S1PR4 (0.43) NQO2ALDH1A1KDM4ENQO1S1PR4
SCHEMBL29769759 0.84 S1PR4 (0.43) NQO2ALDH1A1KDM4ENQO1S1PR4
SCHEMBL10112833 0.81 ERN1 (0.38) POLBTDP1NQO2KMT2AALDH1A1
SCHEMBL31651912 0.81 PDE4B (0.35) NQO2CYP1A2KDM4EHPGDSMN1; SMN2
SCHEMBL30207735 0.79 CYP1A2 (0.41) POLBTDP1NQO2CYP1A2KMT2A
SCHEMBL22621616 0.79 POLB (0.52) POLBTDP1NQO2CYP1A2KMT2A
SCHEMBL2969903 0.79 CYP1A2 (0.41) POLBTDP1NQO2CYP1A2KMT2A
SCHEMBL3792156 0.77 S1PR4 (0.47) NQO2KMT2AALDH1A1KDM4EHPGD
SCHEMBL16043514 0.76 S1PR4 (0.46) NQO2KMT2AALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4637735-A1 DIMETHOXYPHENYL HETEROAROMATIC ALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS ATAI Therapeutics, Inc. (US) 2025-10-29 EP disclosed
US-20250270173-A1 PYRIDINE DERIVATIVES FOR TREATING PSYCHIATRIC DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2025-08-28 US disclosed
EP-3351533-B1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2025-07-23 EP disclosed
WO-2025085701-A1 PYRIDINE DERIVATIVES FOR TREATING PSYCHIATRIC DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2025-04-24 WO disclosed
EP-4511029-A1 PYRIDINE DERIVATIVES FOR TREATING PSYCHIATRIC DISORDERS Gilgamesh Pharmaceuticals, Inc. (US) 2025-02-26 EP disclosed
WO-2024138032-A1 DIMETHOXYPHENYL HETEROAROMATIC ALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS ENTHEOGENIX BIOSCIENCES, INC. (US) 2024-06-27 WO disclosed
WO-2024138032-A1 DIMETHOXYPHENYL HETEROAROMATIC ALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS ENTHEOGENIX BIOSCIENCES, INC. (US) 2024-06-27 WO disclosed
WO-2023205116-A1 PYRIDINE DERIVATIVES FOR TREATING PSYCHIATRIC DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2023-10-26 WO disclosed
WO-2023205116-A1 PYRIDINE DERIVATIVES FOR TREATING PSYCHIATRIC DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2023-10-26 WO disclosed
CN-108290838-B Biaryl derivatives and drugs containing the same 科研制药株式会社 2021-12-31 CN disclosed
US-10647675-B2 Biaryl derivative and medicine containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2020-05-12 US disclosed
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2019-02-21 US disclosed
EP-3351533-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2018-07-25 EP disclosed
CN-108290838-A Biaryl derivatives and drugs containing the same 科研制药株式会社 2018-07-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647675-B2 Biaryl derivative and medicine containing same MAN2B1, CBR3, MANBA POLB 1481/4885TDP1 4417/4885NQO2 497/4885
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME MAN2B1, CBR3, MANBA POLB 1481/4885TDP1 4417/4885NQO2 497/4885
US-20250270173-A1 PYRIDINE DERIVATIVES FOR TREATING PSYCHIATRIC DISORDERS GRIN2C, HTR1A, GRIA4 POLB 4692/4885TDP1 1309/4885NQO2 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.